SOPHiA GENETICS CMO sells 5,000 shares at $7.88

SOPHiA GENETICS SA’s chief medical officer executed a small 5,000‑share 10b5‑1 planned sale, retaining over two hundred thousand shares afterward.

Available on EDGAR 09/16/2026 - 04:02 PM EDT Accepted by SEC EDGAR 09/16/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) reported that Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares on September 14, 2026 in an open-market or private transaction at a weighted average price of $7.8833 per share, pursuant to a duly adopted Rule 10b5-1(c) trading plan, leaving him with 208,387 shares held directly.

Insider Trade Summary

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Menu Philippe

Role Chief Medical Officer

Sold 5,000 shs ($39K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	5,000	$7.8833	$39K

Holdings After Transaction: Ordinary Shares — 208,387 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.78 to $7.99, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 5,000 shares Weighted average sale price: $7.8833 per share Price range of sales: $7.78–$7.99 per share +2 more

5 metrics

Shares sold 5,000 shares Ordinary Shares sold on September 14, 2026

Weighted average sale price $7.8833 per share Ordinary Shares sale on September 14, 2026

Price range of sales $7.78–$7.99 per share Multiple transactions included in the reported weighted average price

Post-transaction holdings 208,387 shares Ordinary Shares directly held by Philippe Menu after the sale

Approximate transaction value $39,416.50 5,000 shares at a weighted average price of $7.8833 per share

Key Terms

Rule 10b5-1(c), weighted average price, Ordinary Shares, open market or private transaction

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"The security title for this transaction is Ordinary Shares."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOPH report for Chief Medical Officer Philippe Menu?

SOPHiA GENETICS SA reported that Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares on September 14, 2026 in a sale characterized as an open-market or private transaction, according to the Form 4 insider filing.

At what price were the SOPH shares sold in this Form 4 transaction?

The shares were sold at a weighted average price of $7.8833 per share. A footnote states they were sold in multiple transactions at prices ranging from $7.78 to $7.99, inclusive.

How many SOPH shares does Philippe Menu hold after this reported sale?

After selling 5,000 shares, Chief Medical Officer Philippe Menu directly holds 208,387 Ordinary Shares of SOPHiA GENETICS SA, as stated in the Form 4 filing.

Was the SOPH insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote explains the sale was made pursuant to a duly adopted trading plan under Rule 10b5-1(c), indicating it followed a pre-arranged trading program.

What is the total dollar value of the SOPH shares sold by Philippe Menu?

Based on 5,000 shares sold at a weighted average price of $7.8833 per share, the transaction’s value is approximately $39,416.50, derived directly from the reported share count and price.

What type of security did Philippe Menu sell in the SOPH Form 4?

Philippe Menu sold Ordinary Shares of SOPHiA GENETICS SA. The Form 4 lists the security title as Ordinary Shares and reports the transaction as a non-derivative sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/14/2026		S		5,000(1)	D	$7.8833(2)	208,387	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.78 to $7.99, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)